RS66227B1 - Kompozicije i postupci za lečenje poremećaja mrežnjače - Google Patents

Kompozicije i postupci za lečenje poremećaja mrežnjače

Info

Publication number
RS66227B1
RS66227B1 RS20241186A RSP20241186A RS66227B1 RS 66227 B1 RS66227 B1 RS 66227B1 RS 20241186 A RS20241186 A RS 20241186A RS P20241186 A RSP20241186 A RS P20241186A RS 66227 B1 RS66227 B1 RS 66227B1
Authority
RS
Serbia
Prior art keywords
seq
sequence
aav
vector
tcu
Prior art date
Application number
RS20241186A
Other languages
English (en)
Serbian (sr)
Inventor
Robin Ali
Takaaki Matsuki
Alexander Smith
Anastasios Georgiadis
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of RS66227B1 publication Critical patent/RS66227B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20241186A 2018-01-12 2019-01-14 Kompozicije i postupci za lečenje poremećaja mrežnjače RS66227B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1800546.2A GB201800546D0 (en) 2018-01-12 2018-01-12 Treatment
EP19701018.4A EP3737423B1 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders
PCT/GB2019/050092 WO2019138250A1 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders

Publications (1)

Publication Number Publication Date
RS66227B1 true RS66227B1 (sr) 2024-12-31

Family

ID=61256183

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20241186A RS66227B1 (sr) 2018-01-12 2019-01-14 Kompozicije i postupci za lečenje poremećaja mrežnjače

Country Status (26)

Country Link
US (2) US11680276B2 (cg-RX-API-DMAC7.html)
EP (1) EP3737423B1 (cg-RX-API-DMAC7.html)
JP (1) JP7289306B2 (cg-RX-API-DMAC7.html)
KR (1) KR102786552B1 (cg-RX-API-DMAC7.html)
CN (1) CN111936172A (cg-RX-API-DMAC7.html)
AU (1) AU2019206314B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014191A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088079A1 (cg-RX-API-DMAC7.html)
DK (1) DK3737423T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091655A1 (cg-RX-API-DMAC7.html)
ES (1) ES2988499T3 (cg-RX-API-DMAC7.html)
FI (1) FI3737423T3 (cg-RX-API-DMAC7.html)
GB (1) GB201800546D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20241483T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068987T2 (cg-RX-API-DMAC7.html)
IL (1) IL275985A (cg-RX-API-DMAC7.html)
LT (1) LT3737423T (cg-RX-API-DMAC7.html)
MX (1) MX2020007366A (cg-RX-API-DMAC7.html)
PH (1) PH12020551071A1 (cg-RX-API-DMAC7.html)
PL (1) PL3737423T3 (cg-RX-API-DMAC7.html)
PT (1) PT3737423T (cg-RX-API-DMAC7.html)
RS (1) RS66227B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006618PA (cg-RX-API-DMAC7.html)
SI (1) SI3737423T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400410T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019138250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906815A1 (en) 2013-03-15 2014-09-18 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
CN113025616B (zh) * 2021-04-21 2023-05-02 中国热带农业科学院橡胶研究所 一种橡胶树泛素基因启动子proHbUBI2及其克隆与应用
WO2022246089A1 (en) * 2021-05-20 2022-11-24 Artema Therapeutics, Inc. Kcnv2 variants and their use
CA3225080A1 (en) * 2021-07-14 2023-01-19 Anastasios GEORGIADIS Kcnv2 gene therapy
WO2023039175A2 (en) * 2021-09-09 2023-03-16 Applied Genetic Technologies Corporation Predictors of achromatopsia treatment efficacy
WO2026150224A1 (en) 2024-12-30 2026-07-16 MeiraGTx Ocular UK Limited Modified adeno-associated virus (aav) viral capsid proteins and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097538A4 (en) * 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
CN103608455B (zh) * 2011-01-07 2019-01-15 应用遗传科技公司 用于治疗色盲和其它疾病的启动子、表达盒、载体、药盒和方法
ES2822551T3 (es) * 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
FI3265178T3 (fi) * 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
WO2017144080A1 (en) * 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells

Also Published As

Publication number Publication date
SI3737423T1 (sl) 2025-03-31
FI3737423T3 (fi) 2024-11-02
DK3737423T3 (da) 2024-10-21
PH12020551071A1 (en) 2021-09-06
ES2988499T3 (es) 2024-11-20
US20200392536A1 (en) 2020-12-17
EP3737423A1 (en) 2020-11-18
US11680276B2 (en) 2023-06-20
EA202091655A1 (ru) 2020-11-20
GB201800546D0 (en) 2018-02-28
SMT202400410T1 (it) 2025-01-14
CN111936172A (zh) 2020-11-13
US12467066B2 (en) 2025-11-11
SG11202006618PA (en) 2020-08-28
KR20200141435A (ko) 2020-12-18
MX2020007366A (es) 2020-09-03
PT3737423T (pt) 2024-10-03
AU2019206314B2 (en) 2025-02-13
PL3737423T3 (pl) 2025-01-27
CA3088079A1 (en) 2019-07-18
IL275985A (en) 2020-08-31
HRP20241483T1 (hr) 2025-01-03
WO2019138250A1 (en) 2019-07-18
HUE068987T2 (hu) 2025-02-28
AU2019206314A1 (en) 2020-08-13
JP2021510301A (ja) 2021-04-22
NZ766316A (en) 2024-05-31
EP3737423B1 (en) 2024-09-18
US20240067989A1 (en) 2024-02-29
JP7289306B2 (ja) 2023-06-09
BR112020014191A2 (pt) 2022-02-22
LT3737423T (lt) 2024-11-25
KR102786552B1 (ko) 2025-03-26

Similar Documents

Publication Publication Date Title
KR102786552B1 (ko) 망막 질환 치료를 위한 조성물 및 방법
CN105980569A (zh) 重组aav-crumbs同源物组合物及治疗lca-8和进行性rp的方法
CN106414474A (zh) 用于视锥细胞中增强的基因表达的组合物和方法
EP3419673B1 (en) Gene therapy for the treatment of a disease of retinal cone cells
AU2018262427B2 (en) Gene therapy for ciliopathies
JP2023116709A (ja) 眼疾患のための遺伝子療法
CN114127296B (zh) Ube3a基因和表达盒及其应用
CN106794262A (zh) 哺乳动物rpe65的高异构水解酶活性突变体
KR20190034221A (ko) Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
CN119731328A (zh) Abca4反式剪接分子
WO2025247393A1 (zh) 用于治疗Prom1相关视网膜疾病的新型治疗药物
KR20230123925A (ko) Neurod1 및 dlx2 벡터
KR20190028389A (ko) 디스펄린병증의 치료를 위한 절단형 디스펄린
KR20230112672A (ko) 신경변성 질환을 위한 유전자 요법
WO2024069144A1 (en) Rna editing vector
EP4370695A1 (en) Retgc gene therapy
KR20240052746A (ko) Kcnv2 유전자 요법
WO2022020548A2 (en) Variant txnip compositions and methods of use thereof for the treatment of degenerative ocular diseases
JP2024521713A (ja) Kcnv2変異体及びその使用
HK40030486A (en) Compositions and methods for treating retinal disorders
HK40030486B (en) Compositions and methods for treating retinal disorders
EA046019B1 (ru) Композиции и способы лечения нарушений сетчатки
CN116670160A (zh) Dlx2载体